Wierling Christoph, Kessler Thomas, Ogilvie Lesley A, Lange Bodo M H, Yaspo Marie-Laure, Lehrach Hans
Alacris Theranostics GmbH, Berlin, Germany; Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Alacris Theranostics GmbH, Berlin, Germany.
Drug Discov Today Technol. 2015 Aug;15:33-40. doi: 10.1016/j.ddtec.2015.07.002. Epub 2015 Aug 8.
The biological processes that keep us healthy or cause disease, as well as the mechanisms of action of possible drugs are inherently complex. In the face of this complexity, attempts at discovering new drugs to treat diseases have alternated between trial-and-error (typically on experimental systems) and grand simplification, usually based on much too little information. We now have the chance to combine these strategies through establishment of 'virtual patient' models, centred on a detailed molecular characterisation of thousands or even, in the future, millions of patients. In doing so, we lay the foundations for truly personalised therapy, as well as a far-reaching virtualisation of drug discovery and development in oncology and other areas of medicine.
维持我们健康或引发疾病的生物过程,以及潜在药物的作用机制本质上都很复杂。面对这种复杂性,研发治疗疾病的新药的尝试在试错法(通常在实验系统上)和过度简化之间交替进行,而过度简化通常是基于极少的信息。现在,我们有机会通过建立“虚拟患者”模型来结合这些策略,该模型以对数以千计甚至未来数以百万计患者的详细分子特征描述为核心。这样做,我们为真正的个性化治疗奠定了基础,也为肿瘤学和其他医学领域药物研发与开发的深度虚拟化奠定了基础。